Use

This test is useful for therapeutic drug monitoring of adalimumab, quantifying adalimumab as part of a profile evaluating patients for loss of response, partial response on initiation of therapy, autoimmune or hypersensitivity reactions, primary nonresponse, reintroduction after drug holiday, endoscopic/computed tomography enterography recurrence in inflammatory bowel disease, acute infusion reactions, and proactive monitoring. It helps in distinguishing pharmacokinetic failure from immunogenicity, and aids in rational dose escalation or switching, optimizing long-term exposure, particularly early in therapy and in high-risk patients. Adalimumab is an anti-TNF therapy, used to treat multiple immune-mediated inflammatory diseases.